85.30 -0.02 (-0.02%)
After hours: 4:28PM EDT
|Bid||0.00 x 4000|
|Ask||0.00 x 3200|
|Day's Range||85.05 - 85.81|
|52 Week Range||76.41 - 89.72|
|PE Ratio (TTM)||41.74|
|Forward Dividend & Yield||1.84 (2.14%)|
|1y Target Est||N/A|
We are upbeat about solid quarterly growth on the prosperous execution of three growth strategies, namely therapy innovation, globalization and a rise in Medtronic's (MDT) economic value.
Medtronic (MDT) focuses on boosting CSH segment. Notably, successful results from The Bifurcation Cohort study will help the company to achieve expanded FDA approval for the Resolute Onyx DES.
I am going to run you through how I calculated the intrinsic value of Medtronic plc (NYSE:MDT) using the discounted cash flow (DCF) method. If you want to learn moreRead More...
As we continue to age and populations grow, demand for new and innovative healthcare solutions is only growing as well. Already preliminary data shows that MOR208 could be a better therapy than the so-called cell therapies when used in combination to cure cancer.
Intricon Corporation (NASDAQ: IIN) is up more than 223% in the past year. After a big move like that, you would expect a small cap like this to be overvalued. It makes small wearable medical devices smaller and better.
Investors on Monday, May 7, cheered the news of former JPMorgan & Co. "I think they need to buy back stock," said Evercore ISI analyst Vijay Kumar in an interview with TheStreet on Tuesday. Noting that Medtronic has cash and short-term investments totaling more than $14 billion, Kumar said repurchasing shares is a way of reassuring the market that the company finds its shares compelling at these levels.
On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.
For about 20 years at JPMorgan Chase & Co., Mike Weinstein covered Medtronic Plc as an analyst, raising his target price on the stock from $42 to $90. Weinstein will start immediately as a senior vice president of strategy, reporting to Chief Financial Officer Karen Parkhill, Medtronic said in a statement Monday. The company has trailed rivals, grappling with natural disasters including hurricanes and wildfires, and man-made issues such as a shortfall in production of its hottest diabetes devices.
May 7 (Reuters) - Lifetech Scientific Corp: * RECEIVES NOTICE FROM MEDTRONIC GROUP THAT MEDTRONIC ENTERED DEAL WITH CHINA EVERBRIGHT LTD & ANOTHER INVESTOR * AS PER DEAL, MEDTRONIC GROUP SELLS 22.4 PERCENT ...
Abbott Laboratories (ABT) received FDA approval for its breakthrough CGM (continuous glucose monitoring) device, Freestyle Libre, in September 2017. For further details, please read Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval. The company received reimbursement approval for the device from the Centers for Medicare & Medicaid Services in January 2018.
On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.
Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.
Key stock index funds rose Thursday as the FANG stocks and other big-cap techs powered big gains in the tech-heavy PowerShares QQQ Trust.
As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.
Over the last month, BSX stock has registered a rise of ~4.2%. The company came out on top in patent infringement litigation against Edwards Lifesciences (EW), for which a hearing is scheduled in May at the German Court of Appeal. On April 16, Boston Scientific announced its acquisition of Nvision Medical Corporation for a cash payment of $150 million and an additional milestone-based payment over the next four years amounting to $125 million.
Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.
The company has been growing aggressively through strategic acquisitions. This month, the company announced the acquisition of Nvision Medical Corporation in the area of women’s health and Securus Medical in the area of electrophysiology. The company is slated to announce its 1Q18 earnings results on April 25. In this article, let’s discuss the company’s Wall Street recommendations and target prices for the next 12 months.
Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.